MEK inhibition suppresses metastatic progression of KRAS-mutated gastric cancer

被引：0
|
作者：
Yamasaki, Juntaro [1 ]
Otsuki, Yuji [1 ]
Masuda, Kenta [2 ]
Saya, Hideyuki [3 ]
Nagano, Osamu [1 ]
机构：
[1] Keio Univ, Sch Med, Div Gene Regulat, IAMR, Keio, Japan
[2] Keio Univ, Dept Obstet Gynecol, Sch Med, Keio, Japan
[3] Fujita Hlth Univ, Div Gene Reg, Fujita Canc Ctr, Toyoake, Aichi, Japan
来源：
CANCER SCIENCE | 2023年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-1140
引用
收藏
页码：377 / 377
页数：1
相关论文
共 50 条
  • [41] Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer
    Yuxiang Wang
    Xian Li
    Xueling Liu
    Yi Chen
    Chunhao Yang
    Cun Tan
    Bobo Wang
    Yiming Sun
    Xi Zhang
    Yinglei Gao
    Jian Ding
    Linghua Meng
    Cancer Biology & Medicine, 2019, 16 (01) : 66 - 78
  • [42] MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines
    Gong, Jun
    Chen, Yuan
    Yang, Lixin
    Pillai, Raju
    Shirasawa, Senji
    Fakih, Marwan
    ANTICANCER RESEARCH, 2017, 37 (06) : 2831 - 2838
  • [43] Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
    Macarulla, T.
    Cervantes, A.
    Tabernero, J.
    Rosello, S.
    Van Cutsem, E.
    Tejpar, S.
    Prenen, H.
    Martinelli, E.
    Troiani, T.
    Laffranchi, B.
    Jego, V.
    von Richter, O.
    Ciardiello, F.
    BRITISH JOURNAL OF CANCER, 2015, 112 (12) : 1874 - 1881
  • [44] RETRACTION: Glutathione peroxidase 2 overexpression promotes malignant progression and cisplatin resistance of KRAS-mutated lung cancer cells
    Wang, Mei
    Chen, Xu
    Fu, Guang
    Ge, Mingjian
    ONCOLOGY REPORTS, 2025, 53 (01)
  • [45] Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
    T Macarulla
    A Cervantes
    J Tabernero
    S Roselló
    E Van Cutsem
    S Tejpar
    H Prenen
    E Martinelli
    T Troiani
    B Laffranchi
    V Jego
    O von Richter
    F Ciardiello
    British Journal of Cancer, 2015, 112 : 1874 - 1881
  • [46] Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer
    Sandhu, Jaideep
    Wang, Chongkai
    Fakih, Marwan
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (02): : 116 - 119
  • [47] Carbamazepine mediated SMARCA4 inhibition as a therapeutic target for KRAS-mutated CRC
    Shaykevich, Aaron
    Chae, Danbee
    Silverman, Isaac
    Bassali, Jeremy
    Louloueian, Netanel
    Siegman, Alexander
    Bandyopadhyaya, Gargi
    Goel, Sanjay
    Maitra, Radhashree
    CANCER RESEARCH, 2024, 84 (06)
  • [48] Noncoding RNA Profile in Reovirus Treated KRAS-Mutated Colorectal Cancer Patients
    Saperstein, Rafael
    Goel, Sanjay
    Maitra, Radhashree
    DISEASES, 2023, 11 (04)
  • [49] Subgroup classification of receptor tyrosine kinase (RTK) pathway activation in KRAS-mutated metastatic carcinoma
    Wang, Y.
    Windham, J. P.
    Samul, R. A.
    Sanidad, M. A.
    Farooqui, A.
    Gorman, B. M.
    Kelly, J. C.
    Meloni-Ehrig, A. M.
    Jones, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [50] Mechanisms linking STK11 loss with metastatic potential in KRAS-mutated lung adenocarcinoma
    Royer, Cole M.
    Bialek, Lauren K.
    Sarausky, Hailey M.
    Prior, Shannon M.
    Nandagopal, Gopika
    Deming, Paula B.
    Seward, David J.
    Scheiber, Melissa N.
    CANCER RESEARCH, 2024, 84 (06)
12345